Background: Despite the lack of randomized trials, nebulized Dornase alpha and hypertonic saline are used empirically to treat atelectasis in mechanically ventilated patients. Our objective was to determine the clinical and radiological efficacy of these medications as an adjunct to standard therapy in critically ill patients.
Methods: Mechanically ventilated patients with new onset (<48 h) lobar or multilobar atelectasis were randomized into three groups: nebulized Dornase alpha, hypertonic (7%) saline or normal saline every 12 h. All patients received standard therapy, including chest percussion therapy, kinetic therapy, and bronchodilators. The primary endpoint was the change in the daily chest X-ray atelectasis score.
Results: A total of 33 patients met the inclusion criteria and were randomized equally into the three groups. Patients in the Dornase alpha group showed a reduction of 2.18±1.33 points in the CXR score from baseline to day 7, whereas patients in the normal saline group had a reduction of 1.00±1.79 points, and patients in the hypertonic saline group showed a score reduction of 1.09±1.51 points. Pairwise comparison of the mean change of the CXR score showed no statistical difference between hypertonic saline, normal saline, and dornase alpha. Airway pressures as well as oxygenation, expressed as PaO(2)/F(I)O(2) and time to extubation also were similar among groups. During the study period the rate of extubation was 54% (6/11), 45% (5/11), and 63% (7/11) in the normal saline, hypertonic saline, and Dornase alpha groups, respectively (p=0.09). No treatment related complications were observed.
Conclusions: There was no significant improvement in the chest X-ray atelectasis score in mechanically ventilated patients with new onset atelectasis who were nebulized with Dornase alpha twice a day. Hypertonic saline was no more effective than normal saline in this population. Larger randomized control trials are needed to confirm our results.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1089/jamp.2011.0954 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Intrapleural fibrinolytic therapy for pleural infections: Outcomes from a cohort study.
Ann Acad Med Singap
December 2024
Respiratory and Critical Care Medicine, Tan Tock Seng Hospital, Singapore.
Introduction: Pleural infections are a significant cause of mortality. Intrapleural fibrinolytic therapy (IPFT) utilising alteplase and dornase is a treatment option for patients unsuitable for surgery. The optimal dose of alteplase is unknown, and factors affecting treatment success in an Asian population are unclear.
View Article and Find Full Text PDFPatterns of Use of β-2 Agonists, Steroids, and Mucoactive Medications to Treat Bronchiolitis in the PICU: U.S. Pediatric Health Information System 2009-2022 Database Study.
Pediatr Crit Care Med
December 2024
Department of Pediatrics, Division of Critical Care, University of Utah, Salt Lake City, UT.
Objectives: Describe β2-agonists, steroids, hypertonic saline (HTS), n-acetylcysteine (NAC), and dornase alfa (DA) use to treat bronchiolitis, factors associated with use, and associations between use and PICU length of stay (LOS).
Design: Retrospective, multicenter cohort study.
Setting: PICUs in the Pediatric Health Information System database.
Streptococcus constellatus Empyema: A Case Highlighting the Need for Timely Surgical Intervention.
Cureus
October 2024
Internal Medicine, Norton Community Hospital, Norton, USA.
This case report explores the intricate challenges of diagnosing and managing empyema caused by , particularly in patients with predisposing factors such as alcohol abuse and underlying respiratory conditions. We present a 34-year-old male patient with a medical history of hypertension, peripheral neuropathy, and alcohol abuse who developed empyema. Despite an initial presentation at another facility with symptoms mimicking a myocardial infarction and unremarkable chest X-ray results, his condition worsened, leading to a subsequent emergency department visit.
View Article and Find Full Text PDFProcess and validity of linking cystic fibrosis patient registry with national Medicaid databases.
J Cyst Fibros
November 2024
Rutgers University Institute for Health, Health Care Policy and Aging Research, New Brunswick, New Jersey, USA; Department of Medicine, Rutgers Robert Wood Johnson Medical School, Piscataway, New Jersey, USA; Department of Biostatistics and Epidemiology, Rutgers School of Public Health, Piscataway, New Jersey, USA. Electronic address:
Article Synopsis
- * A matching algorithm was used to connect 10,616 individuals with CF from CFFPR to Medicaid data, revealing that those linked had significantly higher outpatient visits and antibiotic prescriptions than reported in the CFFPR alone.
- * The study found high costs associated with CF treatment in North Carolina, with pharmacy costs reaching $16.4 million and non-pharmacy costs totaling $7.5 million, highlighting the potential for comprehensive analysis of healthcare utilization and costs for low-income CF patients through linked data.
Novel management of pseudomonas biofilm-like structure in a post-pneumonectomy empyema.
Front Cell Infect Microbiol
November 2024
National Institutes of Health, National Cancer Institute, Thoracic Surgery Branch, Bethesda, MD, United States.
We present a patient with a post-pneumonectomy empyema refractory to surgical debridement and systemic antibiotics. The patient initially presented with a bronchopleural fistula and pneumothorax secondary to tuberculosis (TB) destroyed lung, which required a pneumonectomy with Eloesser flap. Ongoing pleural infection delayed the closure of the Eloesser flap, and thoracoscopic inspection of his chest cavity revealed a green, mucous biofilm-like structure lining the postpneumonectomy pleural cavity.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!